# Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants

- Link: https://www.thailand-business-news.com/pr-news/matwings-demonstrates-closed-loop-protein-ai-through-four-ai-wet-lab-cycles-and-222-protein-variants
- Published: 2026-08-20T18:00:00+07:00
- Author: PR Newswire

**The GenSci148 program illustrates a shift from one-time mutation prediction to
iterative protein engineering under real drug-development constraints**

SHANGHAI, Aug. 20, 2026 /PRNewswire/ — **Shanghai Matwings Technology Co., Ltd. ("
Matwings")** today announced that **GenSci148 Injection**, an investigational ophthalmic
biologic developed by **Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci")**,
has received clinical trial clearance in China for neovascular age-related macular
degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).

Matwings supported the GenSci148 program through four iterative AI–wet lab cycles
covering 222 protein variants. Rather than applying AI as a one-time mutation-prediction
tool, the teams repeatedly used experimental results to redesign both molecules 
and optimization objectives. The program progressed from improving biological activity
to balancing potency, stability, expression, formulation and other development-relevant
properties—illustrating a shift from predicting mutations to engineering therapeutic
proteins under real drug-development constraints.

**Four AI–Wet Lab Cycles, 222 Variants**

Matwings and GenSci implemented a closed-loop workflow combining **AI-guided molecular
design, wet-lab testing, experimental feedback and redesign**.

Across **four iterative cycles**, the teams evaluated **222 protein variants**. 
The first two rounds assessed 92 and 30 variants, respectively, with an initial 
focus on biological activity. The next two rounds evaluated 50 variants each, expanding
the optimization objectives to include high-concentration formulation viscosity 
and broader developability requirements.

Experimental results from each round were incorporated into subsequent design cycles,
allowing not only the molecular designs but also the optimization objectives to 
evolve as evidence accumulated.

The campaign therefore progressed from:

**activity optimization → broader developability optimization → multi-objective 
molecular engineering**

Across the optimization campaign, experimentally tested variants demonstrated improvements
or favorable performance across six development-relevant properties:

  |

**Development Parameter**

  |

**Observed Result**

  |  
 |

**VEGF-A binding affinity**

  |

Up to approximately **10-fold improvement**

  |  
 |

**VEGF-A/C/D functional 
blockade

  |

Up to approximately **3-fold improvement**

  |  
 |

**Nonclinical in vivo activity**

  |

Inhibitory activity observed **84 days after dosing in the 
evaluated retinal model

  |  
 |

**Thermal stability**

  |

**Tm increased by up to approximately 4.5°C**

  |  
 |

**Protein expression**

  |

Increased by up to approximately **27.6%**

  |  
 |

**High-concentration formulation
viscosity

  |

Reduced by approximately **13 cP**

  |

Together, these results reflect optimization across three increasingly demanding
dimensions of therapeutic protein development: biological performance, molecular
developability and formulation-relevant properties.

In the nonclinical retinal model evaluated during the program, the optimized molecule
maintained inhibitory activity 84 days after dosing. Under the specific experimental
conditions tested, it also showed greater inhibition than aflibercept and faricimab.

These findings are preclinical and do not establish comparative clinical efficacy
or safety.

**Beyond Mutation Prediction: Engineering Proteins Under Real Drug-Development Constraints**

Therapeutic protein engineering requires balancing biological activity with stability,
expression, formulation and other development constraints. In the GenSci148 program,
experimental results continuously informed subsequent AI-guided designs, enabling
the optimization process to move beyond a single fixed objective.

Some experimentally validated mutations were located **away from the conventional
target-binding interface**, illustrating how AI-guided exploration can identify 
productive regions of sequence space beyond interface-focused design.

The program also illustrates a broader progression in protein AI validation:

**computational benchmarking → experimental validation → repeated integration within
a real drug-development workflow**

GenSci148 represents the third stage of this progression, with AI-guided design 
and experimental evidence repeatedly linked across successive engineering cycles.

**The Venus Protein AI Stack**

Matwings’ **Venus** protein AI stack has evolved from sequence-centered modeling
toward systems integrating three-dimensional structure, evolutionary information
and task-specific capabilities. Importantly, the AI-guided engineering work supporting
GenSci148 was conducted using** Venus 1.0**, while Venus has since advanced to **
Venus 3.0, represented by VenusREM**, which integrates protein sequence, three-dimensional
structure and evolutionary information for mutation-effect prediction.

Rather than relying on a single model, different components are applied to different
protein R&D and engineering tasks within the broader closed-loop workflow.

  |

**Generation**

  |

**Representative Model(s)**

  |

**Information Integrated**

  |

**Primary Role**

  |  
 |

**Venus 1.0**

  |

Venus 1.0

  |

Protein sequence

  |

Sequence-
centeredmodeling

  |  
 |

**Venus 2.0**

  |

Venus-ProSST

  |

Sequence + 3D structure

  |

Structure-aware 
modeling

  |  
 |

**Venus 3.0**

  |

VenusREM

  |

Sequence + 3D structure + 
evolutionary information

  |

Mutation-effect
prediction

  |  
 |

**Task-Specific 
Models

  |

Venus-FSFP, Venus-Maxwell, Venus-Mine, Venus-RXN, Venus-
Fold

  |

Task-dependent

  |

Protein R&D and 
engineering

  |

_Certain models within the broader Venus portfolio are in development or planned
stages._

Together, these models form a specialist AI stack that can be combined with experimental
data and iterative design across different stages of protein engineering.

**From External Validation to Therapeutic Creation**

The GenSci148 collaboration provides external validation of Matwings’ protein-engineering
capabilities in a real therapeutic development program.

In March 2026, Matwings established **Shanghai Biowings Therapeutics Co., Ltd. ("
Biowings Therapeutics")** to apply the same closed-loop engineering approach to 
internally originated therapeutic programs. Matwings develops the underlying AI 
and protein-engineering technology engine, while Biowings Therapeutics combines 
these capabilities with disease biology and drug-development expertise to create
and advance therapeutic candidates.

**"The real test of AI for science is not whether a model performs well on a benchmark,
but whether it can create measurable value through repeated design–experiment cycles
in an actual R&D program," said Prof. Liang Hong, Founder and Chief Scientist of
Matwings.** "GenSci148 marks an important step from demonstrating individual model
capabilities toward building a repeatable protein-engineering system."

**"Matwings contributed important molecular engineering and optimization capabilities
to the GenSci148 program," said Dr. Lei Jin, CEO of GenSci.** "Rather than relying
on one-time predictions, the teams repeatedly combined AI-guided design with experimental
evidence to improve properties relevant to drug development."

**About Matwings**

**Shanghai Matwings Technology Co., Ltd.** is an AI-driven protein R&D company integrating
specialist AI models, computational molecular design and experimental validation
to support iterative protein engineering and drug development.

For more information, visit [**www.matwings.com**](http://www.matwings.com/).

**About Biowings Therapeutics**

**Shanghai Biowings Therapeutics Co., Ltd.** focuses on AI-enabled therapeutic asset
creation and clinical translation.

**Scientific and Development Notice:** GenSci148 is an investigational product. 
Its safety and efficacy have not been established. Preclinical findings are specific
to the experimental systems and conditions evaluated and may not predict clinical
outcomes.

**Contact:**

Website: [www.matwings.com](https://www.matwings.com/)
E-mail: [public@biowingsthera.com](https://www.thailand-business-news.com/pr-news/public@biowingsthera.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants ](http://www.prnasia.com/story/archive/5030416_CN30416_0?rand=184833)
